{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:02:55Z","timestamp":1760295775883},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.endonu.2013.10.013","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T17:16:09Z","timestamp":1389719769000},"page":"323-328","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["\u00bfNecesitamos nuevos tratamientos para la diabetes tipo 2?"],"prefix":"10.1016","volume":"61","author":[{"given":"Fernando","family":"Gomez-Peralta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Abreu Pad\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.endonu.2013.10.013_bib0005","first-page":"S67","article-title":"Diagnosis and classification of diabetes mellitus","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0010","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2013.10.013_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00592-009-0134-3","article-title":"Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?","volume":"46","author":"Giugliano","year":"2009","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.endonu.2013.10.013_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2010.08.006","article-title":"Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review","volume":"92","author":"Giugliano","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endonu.2013.10.013_bib0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1463-1326.2011.01543.x","article-title":"Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and meta-analysis","volume":"14","author":"Pontiroli","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endonu.2013.10.013_bib0030","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2013.10.013_bib0035","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","article-title":"Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and metaanalysis","volume":"14","author":"Deacon","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endonu.2013.10.013_bib0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/dc08-9026","volume":"32","author":"Skyler","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0045","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2013.10.013_bib0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-151-6-200909150-00137","article-title":"Systematic review: Glucose control and cardiovascular disease in type 2 diabetes","volume":"151","author":"Kelly","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2013.10.013_bib0055","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U. S. diabetes care, 1999-2010","volume":"368","author":"Ali","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2013.10.013_bib0060","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2337\/dc11-1679","article-title":"Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain)","volume":"35","author":"Vinagre","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0065","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)","volume":"28","author":"Ryd\u00e9n","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endonu.2013.10.013_bib0070","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dc12-1391","article-title":"Determinants of weight gain in the action to control cardiovascular risk in diabetes trial","volume":"36","author":"Fonseca","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0075","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/jama.290.14.1884","article-title":"Lifetime risk for diabetes mellitus in the United States","volume":"290","author":"Narayan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2013.10.013_bib0080","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2337\/dc11-1162","article-title":"Trends in death rates among U. S. adults with and without diabetes between 1997 and 2006: Findings from the National Health Interview Survey","volume":"35","author":"Gregg","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1463-1326.2011.01552.x","article-title":"Weight change in people with type 2 diabetes: Secular trends and the impact of alternative antihyperglycaemic drugs","volume":"14","author":"Morgan","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endonu.2013.10.013_bib0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1056-8727(03)00058-8","article-title":"Hypoglycaemia as a barrier to glycemic control","volume":"18","author":"Davis","year":"2004","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.endonu.2013.10.013_bib0095","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2337\/dc12-0916","article-title":"Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: A nationwide population-based study","volume":"36","author":"Hsu","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0100","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2013.10.013_bib0105","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2013.10.013_bib0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1463-1326.2004.00448.x","article-title":"Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents","volume":"7","author":"Goodarzi","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endonu.2013.10.013_bib0115","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Invest"},{"issue":"Suppl 3","key":"10.1016\/j.endonu.2013.10.013_bib0120","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.2337\/diabetes.53.suppl_3.S16","article-title":"Five stages of evolving beta-cell dysfunction during progression to diabetes","volume":"53","author":"Weir","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.endonu.2013.10.013_bib0125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0130","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0168-8227(98)00038-2","article-title":"Assessing the potential for alpha-glucosidase inhibitors in prediabetic states","volume":"40 Suppl","author":"Holman","year":"1998","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endonu.2013.10.013_bib0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/endo.143.2.8623","article-title":"Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity","volume":"143","author":"Poitout","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.endonu.2013.10.013_bib0140","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1463-1326.2007.00745.x","article-title":"Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis","volume":"10","author":"Decker","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endonu.2013.10.013_bib0145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/dmrr.770","article-title":"Beta-cell function and anti-diabetic pharmacotherapy","volume":"23","author":"Del Prato","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.endonu.2013.10.013_bib0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2337\/dc09-1679","article-title":"Inflammation and the incidence of type 2 diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"33","author":"Bertoni","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0155","doi-asserted-by":"crossref","first-page":"E1610","DOI":"10.1210\/jc.2013-2038","article-title":"Does inflammation determine metabolic health status in obese and nonobese adults?","volume":"98","author":"Phillips","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1 Pt 2","key":"10.1016\/j.endonu.2013.10.013_bib0160","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7326\/0003-4819-124-1_Part_2-199601011-00006","article-title":"Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?","volume":"124","author":"Stern","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2013.10.013_bib0165","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2337\/dc11-2219","article-title":"Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes","volume":"35","author":"Cavelti-Weder","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2013.10.013_bib0170","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0735-1097(03)00088-3","article-title":"Atherothrombosis, inflammation, and diabetes","volume":"41","author":"Biondi-Zoccai","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endonu.2013.10.013_bib0175","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00125-006-0297-1","article-title":"Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75)","volume":"49","author":"Stratton","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.endonu.2013.10.013_bib0180","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.endonu.2013.10.013_bib0185","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"}],"container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092213003392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092213003392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T14:02:23Z","timestamp":1565100143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1575092213003392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1575092213003392"],"URL":"https:\/\/doi.org\/10.1016\/j.endonu.2013.10.013","relation":{},"ISSN":["1575-0922"],"issn-type":[{"value":"1575-0922","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00bfNecesitamos nuevos tratamientos para la diabetes tipo 2?","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endonu.2013.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 SEEN. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}